OctoPlus N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 10 jan 2012 - 22:53

Statutaire naam OctoPlus N.V.

Titel OctoPlus announces agreement with leading pharmaceutical company for development of a controlled release formulation

Bericht OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), announces today that it has signed a feasibility agreement with a leading US-based pharmaceutical company, aimed at developing a controlled release formulation of the client’s therapeutic compound for local delivery into joints. The contract announced today covers initial activities in developing a controlled release formulation of an undisclosed compound using our proprietary drug delivery technology PolyActive®. If the evaluation is successful, the project may progress into a full development, manufacturing and licensing agreement. Financial terms of the current agreement are not disclosed.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201201100000000019_OctoPlus announces agreement with leading pharmaceutical company for development of a controlled release formulation.pdf (opens in a new window)

201201100000000019_OctoPlus tekent evaluatiecontract met vooraanstaande farmaceut voor ontwikkeling van een langerwerkende formulering.pdf (opens in a new window)

Datum laatste update: 21 februari 2026